Evoke Pharma Inc. (NASDAQ:EVOK)’s share price traded down 6.4% on Tuesday . The stock traded as low as $2.40 and last traded at $2.48, with a volume of 1,407,206 shares changing hands. The stock had previously closed at $2.65.

Several equities analysts recently weighed in on the stock. Rodman & Renshaw lowered shares of Evoke Pharma from a “buy” rating to a “neutral” rating and set a $2.00 price objective on the stock. in a report on Monday, July 18th. Brean Capital lowered shares of Evoke Pharma from a “buy” rating to a “hold” rating in a report on Monday, July 18th. FBR & Co reaffirmed a “buy” rating on shares of Evoke Pharma in a research note on Friday, July 8th. Finally, Zacks Investment Research downgraded shares of Evoke Pharma from a “buy” rating to a “hold” rating in a research note on Monday, May 16th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $13.34.

The company’s market capitalization is $19.55 million. The stock has a 50 day moving average of $5.58 and a 200 day moving average of $4.74.

Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings results on Wednesday, May 11th. The specialty pharmaceutical company reported ($0.45) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.41) by $0.04. On average, analysts expect that Evoke Pharma Inc. will post ($1.43) EPS for the current fiscal year.

In other Evoke Pharma news, major shareholder Parters Vii L. P. Domain sold 344,120 shares of the business’s stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $4.70, for a total transaction of $1,617,364.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.